Alkermes Plc. (ALKS) SEC Filing 10-Q Quarterly report for the period ending Sunday, September 30, 2018

Earnings Press Release
10-Q Quarterly Report
10-Q QoQ Changes
Alkermes Plc.
Ticker: ALKS CIK: 1520262

Exhibit 99.1


	Alkermes Contacts:
	For Investors:	Sandy Coombs +1 781 609 6377
		Eva Stroynowski +1 781 609 6823
	For Media:	Sherry Feldberg +1 781 609 6276

Alkermes Plc Reports Third Quarter 2018 Financial Results

— Third Quarter Revenues Increased to $248.7 Million, Driven by 24% Year-Over-Year Growth of Proprietary Product Net Sales —

— Company Reports GAAP Net Loss per Share of $0.22 and Diluted Non-GAAP
Earnings per Share of $0.07 —

— Company Increases Financial Expectations for 2018 —

DUBLIN, Ireland, Oct. 23, 2018

— Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2018.

“Our solid results in the quarter were in-line with expectations, driven by the growth of our proprietary commercial products, the continued strength of our royalty and manufacturing business, and the important investments we are making in our late-stage pipeline and commercial organization,” commented James Frates, Chief Financial Officer of Alkermes. “Our diverse business is financially strong and we are well positioned to execute on our strategy to drive value and long-term growth. Based on our outlook for the remainder of the year, today we are raising our financial expectations for 2018, primarily driven by upside from AMPYRA^® revenues.”

Quarter Ended Sept. 30, 2018 Financial Highlights

• Total revenues for the quarter were $248.7 million. This compared to $217.4 million for the same period in the prior year, representing an increase of 14%. Proprietary product net sales for VIVITROL^® and ARISTADA^® were $116.0 million for the quarter, reflecting a 24% increase compared to the same period in the prior year.

• Net loss according to generally accepted accounting principles in the U.S. (GAAP) was $34.4 million for the quarter, or a basic and diluted GAAP net loss per share of $0.22. This compared to GAAP net loss of $36.3 million, or a basic and diluted GAAP net loss per share of $0.24, for the same period in the prior year

• Non-GAAP net income was $11.6 million for the quarter, or a non-GAAP basic and diluted earnings per share of $0.07. This compared to non-GAAP net income of $4.2 million, or a non-GAAP basic and diluted earnings per share of $0.03, for the same period in the prior year.

“The third quarter was highlighted by the launch of ARISTADA INITIO^®¹, the newest addition to the ARISTADA product family. This new offering is resonating with healthcare providers and the early trends are encouraging. ARISTADA INITIO further differentiates ARISTADA in the market and provides an opportunity to address unmet patient need,” stated Jim Robinson, President and Chief Operating Officer of Alkermes. “We are also making important strides with VIVITROL as the product continues to grow and as policymakers continue to activate in their response to the opioid crisis. We look forward to providing updates on our progress.”

Quarter Ended Sept. 30, 2018 Financial Results

Revenues

• Net sales of VIVITROL were $79.9 million, compared to $69.2 million for the same period in the prior year, representing an increase of approximately 15%.

• Net sales of ARISTADAwere $36.1 million, compared to $24.5 million for the same period in the prior year, representing an increase of approximately 48%.

The following information was filed by Alkermes Plc. (ALKS) on Tuesday, October 23, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Alkermes Plc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Alkermes Plc..

Continue

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1520262/000156459018024699/alks-10q_20180930.htm